Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 26141949
Liu R, et al. (2015) CDK1-Mediated SIRT3 Activation Enhances Mitochondrial Function and Tumor Radioresistance. Mol Cancer Ther 14, 2090-102 26141949
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T150-p - SIRT3 (human)
Modsite: MVGAGIStPSGIPDF SwissProt Entrez-Gene
Orthologous residues
SIRT3 (human): T150‑p, SIRT3 (mouse): T85‑p, SIRT3 (rat): T8‑p
Characterization
Methods used to characterize site in vivo mutation of modification site
Disease tissue studied:  brain cancer, glioblastoma, glioma, breast cancer, colorectal cancer, colorectal carcinoma
Relevant cell lines - cell types - tissues:  HCT116 (intestinal), MCF10A1 (epithelial), MDA-MB-231 (breast cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK1 (human) co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing_radiation increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced
Effect of modification (process):  apoptosis, inhibited

S159-p - SIRT3 (human)
Modsite: SGIPDFRsPGSGLYS SwissProt Entrez-Gene
Orthologous residues
SIRT3 (human): S159‑p, SIRT3 (mouse): S94‑p, SIRT3 (rat): S17‑p
Characterization
Methods used to characterize site in vivo mutation of modification site
Disease tissue studied:  brain cancer, glioblastoma, glioma, breast cancer, colorectal cancer, colorectal carcinoma
Relevant cell lines - cell types - tissues:  HCT116 (intestinal), MCF10A1 (epithelial), MDA-MB-231 (breast cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK1 (human) co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing_radiation increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced
Effect of modification (process):  apoptosis, inhibited